Some solid insights in the report - and good pickup on the fact that oncology has tended to push down success rates.
I also found it interesting that there is little to no reference to dermatology trials - which IMO highlights the extent of unmet needs across the various conditions BOT is exploring.
Acne Phase 2 - Probability of Success and Likely Market Response, page-5
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
15.0¢ |
Change
-0.005(3.23%) |
Mkt cap ! $303.9M | |||
| Open | High | Low | Value | Volume |
| 15.5¢ | 15.5¢ | 14.8¢ | $825.3K | 5.486M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 76 | 5701985 | 14.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 15.0¢ | 406420 | 4 |
View Market Depth
| Last trade - 10.36am 21/07/2025 (20 minute delay) ? |
| BOT (ASX) Chart |